ACVR2B

(redirected from ActRIIB)
Also found in: Acronyms, Wikipedia.

ACVR2B

A gene on chromosome 3p22 that encodes activin receptor type IIB, a receptor that forms a complex with other type-I and two type-II  transmembrane serine/threonine kinase receptors for activin, a dimeric growth and differentiating factor belonging to the TGF-beta superfamily of structurally related signalling proteins. Type-I receptors are essential for signalling; type-II receptors are required for binding ligands and expression of type-I receptors. After activin binding, type-I receptors phosphorylate cytoplasmic SMAD transcription factors, which then translocate to the nucleus and interact directly with DNA or in complex with other transcription factors, playing roles in cell differentiation, growth arrest and apoptosis.
References in periodicals archive ?
On September 9, 2010 Shire announced that it had expanded its HGT pipeline by acquiring an exclusive license in markets outside of North America for the ActRIIB class of molecules being developed by Acceleron.
The collaboration will initially investigate ACE-031, Acceleron's lead ActRIIB drug candidate, currently in a Phase 2a trial for the treatment of patients with Duchenne Muscular Dystrophy (DMD).
Shire will receive an exclusive license to Acceleron's ActRIIB molecules, including ACE-031, in markets outside of North America.
creates a freely circulating, decoy version of ActRIIB which interferes
ACE-031, a soluble fusion protein based on the activin receptor type IIB (ActRIIB), is a biologic therapeutic that inhibits signaling through the ActRIIB receptor.
ACE-031, a soluble molecule based on the activin receptor type IIB (ActRIIB), is a biologic therapeutic that inhibits signaling through the ActRIIB receptor.
ActRIIB binds to myostatin (GDF-8) and other negative regulators of muscle mass and strength.